DR. MARTIN ALEXANDER CHEEVER, M.D.
Osteopathic Medicine at Eastlake Ave, Seattle, WA

6075122, Jun 13, 2000

Jun 6, 1995

8/466680

Martin A. Cheever - Mercer Island WA
Mary L. Disis - Renton WA

University of Washington - Seattle WA

C07K 1447, C07K 14705

530350

Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e. g. , by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.

7655239, Feb 2, 2010

Jun 21, 2007

11/821574

Martin A Cheever - Mercer Island WA, US
Mary L Disis - Renton WA, US

University of Washington - Seattle WA

A61K 38/08, C07K 7/06

4241851, 530300, 530327, 530328, 514 2, 514 15

Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e. g. , by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.

2010008, Apr 8, 2010

Dec 2, 2009

12/629651

Martin A. Cheever - Mercer Island WA, US
Mary L. Disis - Renton WA, US

University of Washington - Seattle WA

C07K 7/06

530328

Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e.g., by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.

5726023, Mar 10, 1998

Jun 6, 1995

8/467083

Martin A. Cheever - Mercer Island WA
Mary L. Disis - Renton WA

University of Washington - Seattle WA

G01N 33536, G01N 33541, G01N 33566, C07K 1630

435 71

Methods for the detection, monitoring and treatment of malignancies in which the HER-2/neu oncogene is associated are disclosed. Detection of specific T cell activation (e. g. , by measuring the proliferation of T cells) in response to in vitro exposure to the HER-2/neu protein, or detection of immunocomplexes formed between the HER-2/neu protein and antibodies in body fluid, allows the diagnosis of the presence of a malignancy in which the HER-2/neu oncogene is associated. The present invention also discloses methods and compositions, including peptides, for treating such malignancies.

2003008, May 1, 2003

Jun 7, 1995

08/473762

MARTIN A. CHEEVER - MERCER ISLAND WA, US
DAVID J. PEACE - SEATTLE WA, US

A01N037/18, A61K038/00, C12Q001/68, G01N033/574, A61K039/00

514/002000, 435/007230, 424/277100

Methods for the detection, monitoring and treatment of malignancies are disclosed. Detection of the proliferation of T cells in response to in vitro exposure to a protein expression product of an activated oncogene or cancer-related gene associated with a malignancy, or detection of immunocomplexes formed between the protein expression product and antibodies in body fluid, allows the diagnosis of the presence of a malignancy. The present invention also discloses methods and compositions for treating a malignancy.

5320947, Jun 14, 1994

Jan 13, 1992

7/820409

Martin A. Cheever - Mercer Island WA
David J. Peace - Seattle WA

Washington Research Foundation - Seattle WA

C07K 300, C12Q 100, C12N 500, A01N 6300

435 29

Methods for the detection, monitoring and treatment of malignancies are disclosed. Detection of the proliferation of T cells in response to in vitro exposure to a protein expression product of an activated oncogene or cancer-related gene associated with a malignancy, or detection of immunocomplexes formed between the protein expression product and antibodies in body fluid, allows the diagnosis of the presence of a malignancy. The present invention also discloses methods and compositions for treating a malignancy.

2010016, Jul 1, 2010

Dec 23, 2009

12/646703

Alexander Gaiger - Vienna, AT
Martin A. Cheever - Mercer Island WA, US

A61K 39/395, A61K 39/00, A61K 35/26, C12N 5/00, A61K 38/02, A61K 31/7088, C07K 2/00, C07K 7/06, C07H 21/00

4241301, 4241841, 424 9371, 435375, 514 2, 514 44 R, 530300, 530326, 530327, 530328, 530329, 530330, 536 235

Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.

7115272, Oct 3, 2006

Oct 6, 2000

09/684361

Alexander Gaiger - Seattle WA, US
Martin A. Cheever - Mercer Island WA, US

Corixa Corporation - Research Triangle Park NC
University of Washington - Seattle WA

A61K 38/04, A61K 38/08, A61K 39/00, C07K 7/06, C07K 5/10

4242771, 4241851, 514 2, 514 12, 514 13, 514 14, 514 15, 514 16, 514 17, 514 18, 514885, 530350, 530324, 530325, 530326, 530327, 530328, 530329, 530330

Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise a WT1 polypeptide comprising an immunogenic portion of WT1, wherein said WT1 polypeptide comprises the polypeptide of SEQ ID NO:144. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.

2006012, Jun 8, 2006

Jan 25, 2006

11/340431

Alexander Gaiger - Vienna, AT
Martin Cheever - Mercer Island WA, US

Corixa Corporation (c/o GlaxoSmithKline) - Research Triangle Park NC
University of Washington - Seattle WA

A61K 39/00, A61K 38/19

424184100, 424085100

Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.

2003008, May 1, 2003

Feb 22, 2001

09/791477

Alexander Gaiger - Seattle WA, US
Martin Cheever - Mercer Island WA, US

A61K039/00, A61K039/38, A61K048/00

424/184100, 514/044000

Disclosed are compositions and methods for the diagnosis and therapy of Wilms' tumor antigen-associated cancers, and in particular, malignant pleural mesothelioma. In particular embodiments, the invention provides new, effective methods, compositions and kits for eliciting immune and T cell response to Wilms' tumor antigen polypeptide-derived antigenic fragments, and methods for the use of such compositions for diagnosis, detection, treatment, monitoring, and/or prevention of human malignant pleural mesothelioma